Company Description
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.
Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Brian Sullivan |
Contact Details
Address: 16305 36th Avenue North, Suite 100 Minneapolis, Minnesota 55446 United States | |
| Phone | 763 392 0767 |
| Website | celcuity.com |
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary and Director |
| Vicky Hahne CPA | Chief Financial Officer |
| Jodi Sievers | Head of Investor Relations and Corporate Communications |
| Brent Eilefson | General Counsel |
| Sheri Smith | Acting Head of Clinical Operations |
| Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2026 | ARS | Filing |
| Apr 2, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2026 | 144 | Filing |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 25, 2026 | 8-K | Current Report |
| Mar 24, 2026 | SCHEDULE 13D/A | Filing |
| Mar 9, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |